Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics.
Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products.
Nanotech Business and Law Expert to Join Arrowhead - News Item
Caltech and Arrowhead Research Agree to Form Nanokinetics - News Item
Arrowhead Invests In Insert Therapeutics For Nanotech Drug Delivery Systems - News Item
President Named For Arrowhead Nanotech Subsidiary, Aonexx Technologies - News Item
Arrowhead Research Corporation to Form New Nanotech Subsidiary - News Item
Korea-Based Wisepower Acquires Arrowhead's Subsidiary
Arrowhead Opens New Nanomedicine Company to Commercicalize Anti-Obesity Technology
Unidym Signs Contract with Samsung to Manufacture Carbon Nanotubes
Calando Pharmaceuticals and Nanotope Receive Funds under U.S. Government’s QTDP Program
Nanotope Teams Up with Smith + Nephew to Develop Cartilage Regeneration Product
Nanotechnology Firm, Arrowhead Updates Shareholders on Business Operations
Arrowhead to Discuss its Nanomedicine Portfolio at Bio Investor Forum
Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine
Pioneer in Nanomedicine Joins Arrowhead’s Board of Directors
Arrowhead Research Enters Option Agreement for Obesity-Treating Technology
Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System
Phase 1 CALAA-001 Clinical Trial Shows Systemic siRNA Delivery via Targeted Nanoparticles
Arrowhead Appoints Dr. Andrew von Eschenbach to its Scientific Advisory Board
Arrowhead Research Corporation Appoints New Member to its Scientific Advisory Board
Leader in Carbon Nanotube Technology Announces Partnership with Continental Carbon Company
Arrowhead Increases Ownership in Market Leader in Carbon Nanotube Technology
Arrowhead Research Corporation to Consolidate its Carbon Nanotube Production Capabilities
Dr. Seb Leaper, Dr. Ahmed Abdelkarim
In this interview, AZoNano visits the GEIC to talk with Watercycle Technologies about their membrane technology that is hoping to sustainably localize the UK's lithium supply chain.
In this interview, AZoNano visits the Graphene Engineering and Innovation Centre to talk with Mark Dickie, Composite Applications Manager, about how the GEIC is helping to take graphene composite innovation out of the lab and into the wider industry.
In this interview, we speak with Stanford's Gu Group about their newly developed metal nanocluster-based material that's advancing nanoscale 3D printing.
The MiniCapt® Pro is a remote microbial air sampler that is ideal for the pharmaceutical manufacturing industry.
This product profile outlines the NanoRacer High-Speed AFM from Bruker JPK.
NMR spectroscopy is a characterization technique that is extensively used by chemical researchers.